Updated NETs Clinical Trials

1. Somatic Psychoeducational Intervention

   Conditions: Work Related Stress Interventions: Behavioral: Somatic Psychoeducational Intervention Sponsors: University of Florida Not yet recruiting

2. Irinotecan Liposome in Combination With Capecitabine

   Conditions: Pancreatic Cancer Interventions: Drug: Irinotecan liposome Capecitabine Sponsors: Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center Not yet recruiting

3. Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies

   Conditions: Advanced Solid Tumor; Metastatic Solid Tumor; Refractory Solid Tumor; Cancer; Lung Cancer; Triple Negative Breast Cancer; Breast Neoplasms; Neuroendocrine Tumors; Neuroendocrine Carcinoma Interventions: Drug: CID-078 Monotherapy Sponsors: Circle Pharma Recruiting

4. Institutional Registry of Rare Diseases

   Conditions: Rare Diseases; Amyloidosis; Sarcoidosis; Phacomatosis; Pheochromocytoma; Paraganglioma; Von Hippel-Lindau Disease; Immunoglobulin G4-Related Disease; Demyelinating Diseases; Inborn Errors of Metabolism; Eosinophilic Gastrointestinal Disorders; Hypertrophic Cardiomyopathy; Gaucher Disease; Congenital Adrenal Hyperplasia; Hereditary Angioedema; Pulmonary Hypertension; Wilson Disease; Vascular Anomalies; Mastocytosis; Multiple Endocrine Neoplasia; Inflammatory Bowel Diseases; Prader-Willi Syndrome; Hirschsprung Disease; Cushing Syndrome Sponsors: Hospital Italiano de Buenos Aires Recruiting

5. USPIO Enhanced MR Imaging in CNS Tumours (UMIC)

   Conditions: Vestibular Schwannoma; Glioma, Astrocytic Interventions: Diagnostic Test: USPIO enhanced MRI Sponsors: Northern Care Alliance NHS Foundation Trust Recruiting

6. Oral Protein Supplements for Nutritional and Quality of Life Improvement After Pancreatic Resection in Elderly Patients

   Conditions: Pancreatic Cancer; Cholangiocarcinoma; Intraductal Papillary Mucinous Neoplasm; Neuroendocrine Tumor; Solid Pseudopapillary Tumor Interventions: Dietary Supplement: oral protein supplements; Genetic: placebo Sponsors: Yonsei University Completed

7. Pancreatic Fistula After Minimally Invasive Enucleation

   Conditions: Pancreatic Tumor, Benign; Pancreatic Neuroendocrine Tumor; Solid Pseudopapillary Tumor of the Pancreas Sponsors: Fudan University Completed

8. The Application of the PDCA Management Model in Improving the Diagnostic Accuracy of AIG

   Conditions: Autoimmune Gastritis Interventions: Behavioral: PDCA training Sponsors: Ningbo No. 1 Hospital Not yet recruiting

9. Merck Belzutifan PAS

   Conditions: Von Hippel Lindau Disease; Renal Cell Carcinoma Interventions: Other: Merck Belzutifan PAS in adult patients Sponsors: M.D. Anderson Cancer Center; Merck Sharp & Dohme LLC Not yet recruiting

10. A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)

    Conditions: Gastrointestinal Neuroendocrine Pancreatic Tumor Interventions: Drug: SYHX2008 injection; Drug: Sandostatin LAR@ Sponsors: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Recruiting

11. A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors

    Conditions: Small Cell Lung Cancer; Neuroendocrine Tumors Interventions: Drug: BL-M14D1 Sponsors: Sichuan Baili Pharmaceutical Co., Ltd.; Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. Recruiting

12. 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

    Conditions: Pancreatic Ductal Adenocarcinoma; Cholangiocarcinoma; Gastric Cancer; Bladder Cancer; Hepatocellular Carcinoma; Pheochromocytoma; Ovarian Cancer Interventions: Drug: [18F]FAPI-74; Drug: [18F]FDG Sponsors: National Cancer Institute (NCI) Not yet recruiting

13. [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

    Conditions: Head and Neck Tumors; Kidney Cancers; Small Cell Lung Cancers; Pheochromocytoma/Paragangliomas; Gastrointestinal Neuroendocrine Tumors; Somatostatin Receptor Positive Interventions: Drug: 68Ga-DOTATATE; Drug: [203Pb]VMT-alpha-NET; Drug: [212Pb]VMT-alpha-NET Sponsors: National Cancer Institute (NCI) Not yet recruiting

14. Efficacy of Methylprednisolone Pulses in Neuroendocrine Celles Hyperplasia of Infancy : An Early Phase Study

    Conditions: Neuroendocrine Cell Hyperplasia of Infancy Interventions: Drug: IV Methylprednisolone pulses Sponsors: Assistance Publique - Hôpitaux de Paris Not yet recruiting

15. Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy

    Conditions: Somatostatin Receptor Positive; Gastrointestinal Neuroendocrine Tumors; Pheochromocytoma; Paragangliomas Interventions: Drug: 68Ga-DOTATATE; Drug: [203Pb]VMT-alpha-NET; Drug: [212Pb]VMT-alpha-NET Sponsors: National Cancer Institute (NCI) Not yet recruiting

16. A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

    Conditions: Carcinoma, Neuroendocrine; Tumor, Neuroendocrine; Tumors, Neuroendocrine; Neuroendocrine; Carcinoma; Small Cell; Receptors Interventions: Drug: Belinostat; Drug: Cisplatin; Drug: Etoposide Sponsors: National Cancer Institute (NCI) Not yet recruiting

17. NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

    Conditions: Metastatic Neuroendocrine Prostate Cancer Interventions: Drug: [68Ga]Ga-PSMA-11; Drug: [68Ga]GA-DOTA-TATE; Drug: [68Ga]Ga-NeoB; Drug: [177Lu]Lu-PSMA-617; Drug: [177Lu]Lu-DOTA-TATE; Drug: [177Lu]Lu-NeoB; Drug: L-Lysine HCl-L-Arginine HCl, 2.5 %,; Drug: Gonadotropin-releasing hormone (GnRH) analogues; Drug: GnRH antagonists; Drug: Antiemetics & antinauseants; Drug: Metoclopramide Sponsors: Novartis Pharmaceuticals Recruiting

18. Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent

    Conditions: Central Nervous System (CNS) Lesions; Brain Metastases; Brain Neoplasms; Brain Neoplasms, Benign; Brain Tumor, Primary; Brain Tumor, Recurrent; Brain Tumors; Brain Cancer; Brain Tumor; Brain Neoplasm, Primary; Multiple Sclerosis; Multiple Sclerosis Brain Lesion; Neurofibroma; Acoustic Neuroma; CNS Tumor; CNS Lesion; CNS Metastases; CNS Cancer; CNS Lymphoma Interventions: Drug: RVP-001 Sponsors: Reveal Pharmaceuticals Inc.; National Cancer Institute (NCI) Recruiting

19. Risk Factors for Neuroendocrine Neoplasms

    Conditions: Neuroendocrine Neoplasm of Lung; Neuroendocrine Neoplasm of Gastrointestinal Tract (Disorder) Interventions: Other: Case-control study (no intervention) Sponsors: Bavarian Cancer Registry; Bavarian Association of Statutory Health Insurance Accredited Physicians Not yet recruiting

20. Exploring Methods for Treating Hypergastrinemia in Patients With Autoimmune Gastritis

    Conditions: Autoimmune Gastritis Interventions: Other: oral administration of receives only oral administration of placebo; Other: oral administration of compound digestive enzyme capsule; Other: oral administration of Betaine hydrochloride Sponsors: Jianning Yao Recruiting

21. EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.

    Conditions: Gastrointestinal Cancer; Colon Cancer; Rectal Cancer; Anal Cancer; Esophageal Cancer; Stomach Cancer; Appendix Cancer; Pancreas Cancer; Liver Cancer; Neuroendocrine Tumors Interventions: Other: EQUITY GI Sponsors: Case Comprehensive Cancer Center Not yet recruiting

22. Clinical Application of the J-PET Scanner Prototype

    Conditions: Prostate Cancer; Prostatic Hyperplasia; Prostatic Neoplasms; Prostate Cancer Metastatic; Neuroendocrine Tumors; Neuroendocrine Carcinoma Interventions: Diagnostic Test: J-PET scan Sponsors: Jagiellonian University; University Hospital in Krakow Recruiting

23. Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors

    Conditions: Metastatic Chondrosarcoma; Locally Advanced Chondrosarcoma; Metastatic Sinonasal Adenocarcinoma; Locally Advanced Sinonasal Adenocarcinoma; Metastatic Large-cell Neuroendocrine Carcinoma; Locally Advanced Large-cell Neuroendocrine Carcinoma; Metastatic Olfactory Neuroblastoma; Locally Advanced Olfactory Neuroblastoma; Metastatic Sinonasal Undifferentiated Carcinoma; Locally Advanced Sinonasal Undifferentiated Carcinoma Interventions: Drug: Enasidenib Sponsors: National Cancer Institute (NCI) Recruiting

24. Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as Small Cell, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile Cancer

    Conditions: Small Cell Carcinoma of the Bladder; Small Cell Carcinoma of the Urinary Tract; Squamous Cell Carcinoma of the Bladder; Squamous Cell Carcinoma of the Urinary Tract; Primary Adenocarcinoma of the Bladder; Primary Adenocarcinoma of the Urinary Tract; Renal Medullary Carcinoma; Squamous Cell Carcinoma of the Penis Interventions: Drug: Sacituzumab govitecan; Drug: Atezolizumab Sponsors: National Cancer Institute (NCI) Recruiting

25. A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma

    Conditions: Advanced Neuroendocrine Carcinoma Interventions: Drug: LBL-024 for Injection; Drug: Etoposide Injection; Drug: Cisplatin for Injection; Drug: Carboplatin Injection Sponsors: Nanjing Leads Biolabs Co.,Ltd Recruiting

26. DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

    Conditions: Neuroendocrine Neoplasms Interventions: Drug: BI 764532; Drug: Carboplatin; Drug: Etoposide; Drug: Cisplatin Sponsors: Boehringer Ingelheim Recruiting

27. Using Novel Imaging to More Safely Treat Neuroendocrine Tumors

    Conditions: Neuroendocrine Tumors; Somatostatin Receptor-positive Neuroendocrine Tumor Sponsors: University of Wisconsin, Madison Not yet recruiting

28. "Receptor Radionuclide Therapy With 177Lu-DOTATOC

    Conditions: Neuroendocrine Tumors; Paraganglioma; Pheochromocytoma Interventions: Drug: 177Lu-DOTATOC Sponsors: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori Recruiting

29. Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial

    Conditions: Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8; Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8; Locally Advanced Merkel Cell Carcinoma; Metastatic Merkel Cell Carcinoma; Refractory Merkel Cell Carcinoma; Unresectable Merkel Cell Carcinoma Interventions: Drug: Avelumab; Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Procedure: Magnetic Resonance Imaging; Procedure: Positron Emission Tomography; Drug: Tuvusertib Sponsors: National Cancer Institute (NCI) Recruiting

30. The Role of Glucocorticoids to Maintain Energy Homeostasis During Starvation (Gluco-Starve)

    Conditions: Glucocorticoid Effect Interventions: Drug: Metyrapone 250 mg Oral Tablets; Drug: Hydrocortisone 19.9mg s.c., pulsatile with a flow rate of 10μl/s; Drug: Placebo 250 mg Tablets; Drug: Placebo (0,9% NaCl solution) Sponsors: Eleonora Seelig Completed

31. Comparing Retreatment of 177Lu-DOTATATE PRRT Versus Everolimus in Patients With Metastatic Unresectable Midgut Neuroendocrine Tumors, NET RETREAT Trial

    Conditions: Metastatic Midgut Neuroendocrine Tumor; Metastatic Midgut Neuroendocrine Tumor G1; Metastatic Midgut Neuroendocrine Tumor G2; Unresectable Midgut Neuroendocrine Tumor Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Drug: Everolimus; Drug: Lutetium Lu 177 Dotatate; Other: Quality-of-Life Assessment; Other: Questionnaire Administration Sponsors: National Cancer Institute (NCI) Recruiting

32. Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors

    Conditions: Metastatic Neuroendocrine Tumor Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Drug: Lutetium Lu 177 Dotatate; Procedure: Magnetic Resonance Imaging; Drug: Triapine Sponsors: National Cancer Institute (NCI) Recruiting

33. Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors

    Conditions: Metastatic Pancreatic Neuroendocrine Tumor; Pancreatic Neoplasm; Stage III Pancreatic Neuroendocrine Tumor AJCC v8; Stage IV Pancreatic Neuroendocrine Tumor AJCC v8; Unresectable Pancreatic Neuroendocrine Tumor Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Drug: Lutetium Lu 177 Dotatate; Procedure: Magnetic Resonance Imaging; Procedure: Positron Emission Tomography; Drug: Sunitinib Malate Sponsors: National Cancer Institute (NCI) Recruiting

34. Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors

    Conditions: Neuroendocrine Tumors; Neuroendocrine Tumor of the Lung; Neuroendocrine Tumor of Pancreas; Neuroendocrine Carcinoma Metastatic; Neuroendocrine Tumor Carcinoid; Carcinoid Tumor of GI System; Carcinoid Tumor; Paraganglioma; Pheochromocytoma; Small-cell Lung Cancer Interventions: Drug: [212Pb]VMT-α-NET; Drug: [212Pb]VMT-α-NET Sponsors: Perspective Therapeutics Recruiting

35. A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

    Conditions: Small Cell Lung Cancer; Neuroendocrine Carcinoma Interventions: Drug: RO7616789; Drug: Tocilizumab Sponsors: Hoffmann-La Roche Recruiting

36. Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

    Conditions: Advanced Solid Tumors Interventions: Drug: ABBV-706; Drug: Cisplatin; Drug: Budigalimab; Drug: Carboplatin Sponsors: AbbVie Recruiting

37. Circulating Tumour Cells as Biomarkers to Predict Prostate Cancer Metastasis for Treatment Stratification of Cancer

    Conditions: Prostate Cancer Interventions: Diagnostic Test: CTC Blood Test Sponsors: Queen Mary University of London; University College London Hospitals Active, not recruiting

38. Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

    Conditions: GEP-NET; Gastroenteropancreatic Neuroendocrine Tumor; Gastroenteropancreatic Neuroendocrine Tumor Disease; Neuroendocrine Tumors; Carcinoid; Carcinoid Tumor; Pancreatic NET Interventions: Drug: RYZ101; Drug: Everolimus; Drug: Sunitinib; Drug: Octreotide; Drug: Lanreotide Sponsors: RayzeBio, Inc. Recruiting

39. Nivolumab and Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults

    Conditions: Craniopharyngioma, Child; Craniopharyngioma; Recurrent Craniopharyngioma Interventions: Drug: Nivolumab; Drug: Tovorafenib Sponsors: Sabine Mueller, MD, PhD; Bristol-Myers Squibb; Day One Biopharmaceuticals, Inc. Recruiting

40. Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET

    Conditions: Small-cell Lung Cancer; Neuroendocrine Carcinoma Interventions: Drug: Iadademstat; Drug: Paclitaxel Sponsors: Fox Chase Cancer Center; Oryzon Genomics S.A. Recruiting

41. Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.

    Conditions: Neuroendocrine Tumors Interventions: Drug: 177Lu-DOTATOC; Drug: Capecitabine Sponsors: Lund University Hospital Recruiting

42. A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

    Conditions: Acromegaly; GEP-NET Interventions: Drug: Debio 4126; Drug: Sandostatin LAR; Drug: Somatuline ATG Sponsors: Debiopharm International SA Active, not recruiting

43. Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

    Conditions: Atypical Teratoid/Rhabdoid Tumor; Epithelioid Sarcoma; Kidney Medullary Carcinoma; Malignant Solid Neoplasm; Poorly Differentiated Chordoma; Recurrent Atypical Teratoid/Rhabdoid Tumor; Recurrent Chordoma; Recurrent Epithelioid Sarcoma; Recurrent Kidney Medullary Carcinoma; Recurrent Malignant Solid Neoplasm; Recurrent Rhabdoid Tumor; Refractory Atypical Teratoid/Rhabdoid Tumor; Refractory Chordoma; Refractory Epithelioid Sarcoma; Refractory Kidney Medullary Carcinoma; Refractory Malignant Solid Neoplasm; Refractory Rhabdoid Tumor; Rhabdoid Tumor Interventions: Biological: Atezolizumab; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Other: Fludeoxyglucose F-18; Procedure: Magnetic Resonance Imaging; Procedure: Positron Emission Tomography; Biological: Tiragolumab; Procedure: X-Ray Imaging Sponsors: National Cancer Institute (NCI) Recruiting

44. Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)

    Conditions: Neuroendocrine Tumors; Carcinoma, Neuroendocrine Sponsors: National Cancer Institute (NCI) Recruiting

45. A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies

    Conditions: Solid Tumor; Clear Cell Renal Cell Carcinoma; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma; Neuroendocrine Tumors; MSI-H Cancer; Cancer With A High Tumor Mutational Burden; Extensive-stage Small-cell Lung Cancer Interventions: Drug: 23ME-00610 Sponsors: 23andMe, Inc. Active, not recruiting

46. EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers

    Conditions: Neoplasms; Neoplasm Metastasis; Metastatic Gastrointestinal Carcinoid Tumor Interventions: Drug: EMB-01 Sponsors: Shanghai EpimAb Biotherapeutics Co., Ltd.; Labcorp Corporation of America Holdings, Inc Recruiting

47. Multicenter Retrospective Database on Prognostic and Predictive Factors in Patients With Neuroendocrine Tumors

    Conditions: Neuroendocrine Tumors; Carcinoma;Endocrine Sponsors: Latin American Cooperative Oncology Group Active, not recruiting

48. A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG

    Conditions: Prostate Cancer; Breast Cancer; Neuroendocrine Tumors Interventions: Diagnostic Test: Total-body PET imaging Sponsors: University of California, Davis; Lantheus Medical Imaging Enrolling by invitation

49. Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

    Conditions: Advanced Extrapulmonary Neuroendocrine Carcinoma; Metastatic Extrapulmonary Neuroendocrine Carcinoma; Recurrent Extrapulmonary Neuroendocrine Carcinoma; Unresectable Extrapulmonary Neuroendocrine Carcinoma Interventions: Biological: Atezolizumab; Procedure: Biospecimen Collection; Drug: Carboplatin; Drug: Cisplatin; Procedure: Computed Tomography; Drug: Etoposide; Procedure: Magnetic Resonance Imaging; Other: Patient Observation Sponsors: National Cancer Institute (NCI) Recruiting

50. PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours

    Conditions: Neuroendocrine Tumors Interventions: Drug: Talazoparib Sponsors: Peter MacCallum Cancer Centre, Australia Recruiting